IgGenix Inc, a US-based preclinical antibody discovery and development company, announced on Monday that it has presented data on its lead candidate, IGNX001, an IgG4 monoclonal antibody-based therapeutic for peanut allergy, at the 2024 Annual Conference of the Australasian Society of Clinical Immunology and Allergy (ASCIA) in Adelaide, Australia.
Michael O'Sullivan, MBBS, FRACP, FRCPA, lead investigator, presented information on the company's Phase 1 human clinical trial in peanut allergy. The ACCELERATE Peanut study is active and screening and will assess the safety and tolerability of IGNX001, a therapeutic candidate that is intended to provide the potential for rapid protection for peanut allergic patients.
Derek Croote PhD, IgGenix chief technology officer and co-founder, presented preclinical data on IGNX001, demonstrating robust protection against peanut-mediated mast cell activation, and against anaphylaxis in a murine model of peanut allergy.
The Journal of Allergy and Clinical Immunology has published the complete preclinical findings.
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma